Pharvaris NV

Pharvaris maintains a strong liquidity position with EUR 291.7 million in cash and equivalents, representing 96.7% of total assets. The company's current ratio of 10.11 indicates a robust ability to cover short-term liabilities, and its debt-to-equity ratio of 0.0 suggests no material leverage risk. However, negative operating and free cash flows of EUR -137.1 million and EUR -175.4 million, respectively, highlight ongoing cash burn. Profitability metrics are negative, with a return on equity of -64.77% and return on assets of -58.28%, both significantly below industry norms for biotechnology firms. The company reported a net loss of EUR 175.7 million, driven by operating losses of EUR 169.8 million. These results suggest operational inefficiencies or high R&D costs typical in early-stage biotech firms. Pharvaris operates as a single-segment entity, with no disclosed geographic revenue breakdown. This lack of diversification increases exposure to regional regulatory or market risks, though the company's EUR 291.7 million cash position provides a buffer against short-term volatility. The company's growth trajectory is uncertain, with no disclosed revenue history and negative operating cash flows. Analysts have assigned a mean price target of EUR 46.57, implying a 57% upside from the current market price of EUR 29.68. However, the absence of revenue growth data and ongoing losses suggest a high-risk investment profile. Risk factors include the absence of immediate liquidity or dilution flags, but the company's negative cash flows and high price-to-book ratio of 7.16 indicate valuation concerns. No dilution risk is currently flagged, and the company has not issued additional shares in the latest reporting period. Recent events include the publication of the latest financial report (HA-latest), which details the company's ongoing losses and strong liquidity position. No material regulatory or litigation events were disclosed in the latest filings.